Evaluation of a surrogate marker: validity and efficiency

Keywords

Surrogate endpoint, Surrogate data, Surrogate model, Clinical endpoint, Computer science

References

• Quantifying the Effect of the Surrogate Marker by Information GainYongming Qu, Michael Case — 2007
• Demythologizing the high costs of pharmaceutical researchDonald W. Light, Rebecca Warburton — 2011
• Criteria for the validation of surrogate endpoints in randomized experiments.Marc Buyse, Geert Molenberghs — 1998
• Estimating the proportion of treatment effect explained by a surrogate marker by D. Y. Lin, T. R. Fleming and V. De Gruttola, Statistics in Medicine, 16, 1515–1527 (1997)Philippe Flandre, Yacine Saïdi — 1999
• Quantifying the indirect treatment effect via surrogate markersYongming Qu, Michael Case — 2006
• A method to assess the proportion of treatment effect explained by a surrogate endpointZhengqing Li, Michael P. Meredith, Mohammad S. Hoseyni — 2001
• The price of innovation: new estimates of drug development costs.Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski — 2003
• Statistical validation of intermediate endpoints for chronic diseases.Laurence S. Freedman, Barry I. Graubard, Arthur Schatzkin — 1992
• Proportion of treatment effect (PTE) explained by a surrogate markerCong Chen, Hongwei Wang, Steven Snapinn — 2003
• Surrogate endpoints in clinical trials: definition and operational criteria.Ross L. Prentice — 1989
• Prentice's Approach and the Meta‐Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate EndpointsAriel Alonso, Geert Molenberghs, Tomasz Burzykowski — 2004
• Solid partnerships help company expand2012

Cited by

• Clinical and epidemiological issues and applications of mammographic densityValentina Assi — 2014
• Statistical evaluation of surrogate markers: Validity, efficiency, and sensitivityYongming Qu — 2013
• Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damageR Andrew Moore — 2013
• Sensitivity in statistical evaluation of biomarkersWen Li, Yongming Qu, Pandurang M. Kulkarni — 2013
• Monitoring Severity of Multiple Organ Dysfunction Syndrome: New and Progressive Multiple Organ Dysfunction Syndrome, Scoring SystemsKatri Typpo, Jacques Lacroix — 2017
• Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: Systematic review.Thomas Harder, Judith Koch, Ole Wichmann — 2017
• Challenges of Modeling Biomarker Effects on Time-to-Event OutcomesTuo Wang, Yongming Qu — 2026
• Process mining of breast cancer care pathways from routine electronic medical records: coordination patterns, bottlenecks, and hospital-level variationTing Song, Su C. Ang, Kimberley J. Davis — 2026

Related papers

• Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials.Ravi B. Patel, Muthiah Vaduganathan, Ayman Samman‐Tahhan — 2016
• On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection.Solimar Gonçalves Machado, M H Gail, S S Ellenberg — 1990
• Surrogate endpoints in clinical trials: cancer.Susan S. Ellenberg, J. Michael Hamilton — 1989
• Surrogate endpoints in randomized cardiovascular clinical trialsMichaël Domanski, Stuart Pocock, Corine Bernaud — 2011
• Non-inferiority Trials Using a Surrogate Marker as a Primary Endpoint: An Increasing Phenotype in Cardiovascular TrialsBehnood Bikdeli, César Caraballo, John Welsh — 2020
• Progression-free survival as a surrogate for overall survival: a new paradigm?Debashis Ghosh — 2008
• Criteria for surrogate end pointsHua Chen, Zhi Geng, Jinzhu Jia — 2007